RecruitingPhase 2NCT06756308
A Study of Enasidenib in People With T-Cell Lymphoma
Studying Angioimmunoblastic T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Zachary Epstein-Peterson, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Enasidenib(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (8)
- Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts, United States
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Cancer Center (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity), Commack, New York, United States
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States
- Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale, New York, United States
Collaborators
Bristol-Myers Squibb · The Leukemia and Lymphoma Society
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06756308 on ClinicalTrials.govOther trials for Angioimmunoblastic T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07168317Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITLThe Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE3NCT06522737A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeSecuraBio
- RECRUITINGPHASE2NCT07058103Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITLThe Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1NCT06393738A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.Arvinas Inc.
- ACTIVE NOT RECRUITINGPHASE4NCT07046182Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma ForesightZhengzhou University
- ACTIVE NOT RECRUITINGPHASE3NCT03703375Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaCelgene